uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Core Viewpoint - uniQure N.V. has successfully closed a public offering of 6,736,841 ordinary shares at a price of $47.50 per share, raising approximately $345 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering included 947,368 ordinary shares from the underwriters' option and pre-funded warrants for 526,316 ordinary shares [1]. - The offering was conducted under an automatically effective shelf registration statement filed with the SEC [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for commercialization readiness activities, potential launch of AMT-130, development of other clinical candidates, business development initiatives, research projects, and general corporate purposes [2]. Group 3: Company Background - uniQure is a leader in gene therapy, focusing on transformative therapies for severe medical conditions, with a notable achievement being the approval of its gene therapy for hemophilia B [6]. - The company is advancing a pipeline of gene therapies targeting Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases [6].